The Medical University of Innsbruck is a university in Innsbruck, Austria. It used to be one of the four historical faculties of the Leopold-Franzens-Universität Innsbruck and became an independent university in 2004.

During the past decade, Innsbruck University Hospital conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 5 clinical trials were completed, i.e. on average, 22.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Innsbruck University Hospital" #1 sponsor was "Medical University Innsbruck" with 12 trials, followed by "Austrian Breast & Colorectal Cancer Study Group" with 8 trials sponsored, "AOP Orphan Pharmaceuticals AG" with 3 trials sponsored, "Celgene" with 3 trials sponsored and "Incyte Corporation" with 3 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Innsbruck University Hospital" #1 collaborator was "Hoffmann-La Roche" with 5 trials as a collaborator, "Astellas Pharma GmbH" with 2 trials as a collaborator, "Institute of Mountain Emergency Medicine" with 2 trials as a collaborator, "Lund University" with 2 trials as a collaborator and "Merck Gesellschaft mbH, Austria" with 2 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "Innsbruck University Hospital" are "Rectal Cancer" (4 trials), "Polycythemia Vera" (3 trials), "Acute Myeloid Leukemia" (2 trials), "Alpine Accident" (2 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "Innsbruck University Hospital" in a lesser frequency.

Most popular intervention types in "Innsbruck University Hospital" are "Drug" (30 trials), "Other" (8 trials), "Device" (4 trials), "Procedure" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Gemcitabine" (3 trials), "Oxaliplatin" (3 trials), "Alemtuzumab" (2 trials) and "Capecitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Innsbruck University Hospital" are 54 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Innsbruck University Hospital". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 38 completed trials in Innsbruck University Hospital, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Innsbruck University Hospital, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".